GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB has provided positive feedback on ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 17, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel trea ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 17, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB , a company discovering and developing novel treatments for Parkinson's ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,500 ...

Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

A range of preclinical and Phase 1 clinical studies suggest AV-101’s therapeutic potential in multiple CNS indications, including levodopa-induced dyskinesia, neuropathic pain, and seizures.

A range of preclinical and Phase 1 clinical studies suggest AV-101’s therapeutic potential in multiple CNS indications, including levodopa-induced dyskinesia, neuropathic pain, and seizures. The U.S.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based ...

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, ...

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, ...